Clinical Trial Update: A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, local tolerability, pharmacokinetics and pharmacodynamics of LDE225 (sonidegib) for skin basal cell carcinomas in Gorlin syndro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Nevoid Basal Cell Carcinoma Syndrome

Drugs mentioned

• LDE225 (sonidegib) (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients | Phase 2 | Status: COMPLETED | Results posted: 2015-09-21